The following information provides guidance to health care providers attending to the medical needs of HIV-infected adults (including pregnant women) or children displaced from disaster areas who have not yet secured HIV care in the areas where they have relocated.
(*)
- HHS Panel on Antiretrov...iral Guidelines for Adults and Adolescents
- HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission
- HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children
- HHS Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults & Adolescents
- HHS Panel on Guidelines for the Prevention and Treatment of Opportunistic Infection in HIV-Infected Children
more
This report, written in partnership with various Royal Medical Colleges and Public Health England, sets out the essential actions to improve the physical health of adults with severe mental illness (SMI) across the NHS. The report makes practical recommendations for changes that will help adults wit...h SMI to receive the same standards of physical healthcare as the general population and reduce the risk of premature death.
more
HIV, viral hepatitis and STI epidemics, particularly among people who inject drugs and other key populations, continue to be fuelled by laws and policies criminalizing sex work; drug use or possession; diverse forms of gender expression and sexuality; stigma and discrimination; gender discrimination...; violence; lack of community empowerment and other violations of human rights. These sociostructural factors limit access to health services, constrain how these services are
delivered and diminish their effectiveness.
more
The END TB Strategy
Интеграция совместного оказания услуг в связи с ТБ и ВИЧ во всеобъемлющий пакет помощи для потребителей инъекционных наркотиков
Accessed on 04.04.2023
The Drugs for Neglected Diseases initiative (DNDi) is an international
non-profit organization that discovers, develops, and delivers safe,
effective, and affordable treatments for the most neglected patients
At the forefront of DNDi’s efforts to develop new treatments is the need to understand the realities and treatment needs of patients and health care staff in the field. The ultimate goal for human African trypanosomiasis (HAT) is a truly simplified
treatment which can be orally administered, impl...emented at the primary health care level, and effective against both stages of the disease.
more
Doc. No.: INS/GDL/001-(Annexes)
Accessed on 04.04.2023
A Iniciativa Medicamentos para Doenças Negligenciadas (DNDi) é uma organização
internacional sem fins lucrativos que disponibiliza medicamentos seguros, eficazes
e acessíveis para doenças negligenciadas, desde o laboratório até sua chegada às
mãos das popula...ções mais vulneráveis do mundo.
more
Accessed on 04.04.2023
La Iniciativa Medicamentos para Enfermedades Olvidadas (DNDi) es una organización
internacional sin fines de lucro que proporciona tratamientos seguros, eficaces y
asequibles para los pacientes más desatendidos, desde el laboratorio hasta su llegada
a las manos de ...las poblaciones más vulnerables del mundo.
more
Emergence of antimicrobial resistance is a result of the use, overuse and misuse of antibiotics both in humans and animals. In Ethiopia, there are indications on the misuse of antibiotics by health care providers’, unskilled practitioners, and drug consumers. These coupled with rapid spread of res...istant bacteria and inadequate surveillance contributed to the problem. Bacterial infections are the major causes of death in Ethiopia. Studies on antibacterial resistance and on bacterial infections have shown that emerging antibacterial resistance threatens the management of bacterial infections; however, the prevention and containment has received far too little attention.
more
Introduction Pharmacovigilance (PV) systems to monitor drug and vaccine safety are often inadequate in sub-Saharan
Africa. In Malawi, a PV enhancement initiative was introduced to address major barriers to PV.
Objective The objective of this initiative was to improve reporting of adverse events (A...Es) by strengthening passive safety
surveillance via PV training and mentoring of local PV stakeholders and healthcare providers (HCPs) at their own healthcare
facilities (HCFs).
Methods An 18-month PV training and mentoring programme was implemented in collaboration with national stakeholders,
and in partnership with the Ministry of Health, GSK and PATH. Two-day training was provided to Expanded Programme on
Immunisation coordinators, identified as responsible for AE reporting, and four National Regulatory Authority representa-
tives. Abridged PV training and mentoring were provided regularly to HCPs. Support was given in upgrading the national
PV system. Key performance indicators included the number of AEs reported, transmission of AE forms, completeness of
reports, serious AEs reported and timeliness of recording into VigiFlow.
Results In 18 months, 443 HCPs at 61 HCFs were trained. The number of reported AEs increased from 22 (January 2000 to
October 2016) to 228 (November 2016 to May 2018), enabling Malawi to become a member of the World Health Organization
Programme for International Drug Monitoring. Most (98%) AE report forms contained mandatory information on reporter,
event, patient and product, but under 1% were transmitted to the national PV office within 48 h.
Conclusion Regular PV training and mentoring of HCPs were effective in enhancing passive safety surveillance in Malawi,
but the transmission of reports to the national PV centre requires further improvement.
more
To support its R&D activities on Chagas disease, DNDi launched the Chagas Clinical Research Platform (CCRP). The platform brings together partners, experts, and stakeholders to provide support for evaluation and development of new treatments for Chagas disease. The patient-centred platform aims to f...acilitate clinical research, provide a forum for technical discussions, develop a critical mass of expertise, and strengthen institutional research capacities. In addition, it identifies and reviews priority needs, works towards standardization of methodology to assess drug efficacy and reviews alternatives for using current approved drugs (new schemes, doses, combination) and special scenarios (resistance).
more
Leishmaniasis is a climate-sensitive disease. Changes in
temperature, rainfall, and humidity can have strong impacts on
the sandfly vector, altering their distribution and influencing their
survival and population sizes. Increased temperatures shorten
vector development time, reduce Leishmania p...arasite incubation
time, and increase vector biting rates, allowing transmission
in areas not previously endemic for the disease. Poor and
marginalized communities will be hit disproportionately harder by
the effects of climate change, and droughts, famines, and floods
can also lead to displacement and migration of immunologically
naive people to areas where leishmaniasis is endemic, posing a
threat of leishmaniasis outbreaks.
more